Hollings Home  
 
Steven A Rosenzweig, PhD
Professor of Cell and Molecular Pharmacology
College of Medicine
MUSC

Email: rosenzsa@musc.edu
 
       Print This Page
       
 
 


 

Steven A Rosenzweig, PhD

Return to Search Page  

Research Interest:

My research addresses dysregulation of the insulin-like growth factor (IGF) system in breast cancer, prostate cancer, and squamous cell carcinoma of the head and neck (HNSCC). This work is aimed at inhibiting signaling cascades elicited by the IGF-1 receptor (IGF-1R), leading to cell proliferation and cell motility underlying enhanced tumorigenicity. HNSCC is the sixth most prevalent cancer worldwide with South Carolina leading the nation in incidence. Associated with its poor prognosis, HNSCC is often diagnosed at a late stage, when metastatic disease is present. Metastasis is a complex, ordered process that includes changes specifying epithelial to mesenchymal transition (EMT), with little being known about the molecular details of HNSCC metastasis both locoregionally to lymph nodes or to distant sites. My colleagues and I have shown that IGF-1R activation in HNSCC cells stimulates vascular endothelial growth factor (VEGF) secretion, leading to an autocrine signaling cascade by activating VEGFR-2 (Flk-1/ KDR). This is consistent with VEGF’s known ability to regulate tumor progression, metastasis, and its association with poor HNSCC prognosis. The goal of this work is to establish that IGF-1R activity contributes to the tumorigenicity of HNSCC both by direct signaling activities and indirectly by increasing VEGF expression and autocrine action. These studies have uncovered a novel role for VEGF action as an autocrine/paracrine regulator of the invasive behavior of HNSCC cells contributing to metastatic progression.

Positions:
Associate Director of Shared Resources, Hollings Cancer Center, Medical University of South Carolina

Selected Publications:

1.Jezierska-Drutel A, Rosenzweig SA, Neumann CA. Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res. .119:107-25, 2013.
View in: PubMed

2.Rossa C, Sommer G, Spolidorio LC, Rosenzweig SA, Watson DK, Kirkwood KL. Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion. PLoS One. .7(9):e45197, 2012. PMCID: PMC3445460
View in: PubMed

3.Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol. .83(8):1041-8, 2011. PMCID: PMC3299940
View in: PubMed

4.Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. .80(8):1115-24, 2010. PMCID: PMC2934757
View in: PubMed

5.Swain M, Slomiany MG, Rosenzweig SA, Atreya HS. High-yield bacterial expression and structural characterization of recombinant human insulin-like growth factor binding protein-2. Arch Biochem Biophys. .501(2):195-200, 2010. PMCID: PMC2934857
View in: PubMed

6.Lucas JT, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene. .29(31):4449-59, 2010. PMCID: PMC2921319
View in: PubMed

7.Mulligan JK, Rosenzweig SA, Young MR. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother. .33(2):126-35, 2010. PMCID: PMC3333835
View in: PubMed

8.Swain M, Thirupathi R, Krishnarjuna B, Eaton EM, Kibbey MM, Rosenzweig SA, Atreya HS. Spontaneous and reversible self-assembly of a polypeptide fragment of insulin-like growth factor binding protein-2 into fluorescent nanotubular structures. Chem Commun (Camb). .46(2):216-8, 2009.
View in: PubMed

9.Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol. .70(6):375-82, 2009. PMCID: PMC2746465
View in: PubMed

10.Slomiany MG, Black LA, Kibbey MM, Tingler MA, Day TA, Rosenzweig SA. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett. .248(2):269-79, 2006.
View in: PubMed

11.Slomiany MG, Rosenzweig SA. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther. .318(2):666-75, 2006.
View in: PubMed

12.Robinson SA, Rosenzweig SA. Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling. Biochem Pharmacol. .72(1):53-61, 2006.
View in: PubMed

13.Slomiany MG, Black LA, Kibbey MM, Day TA, Rosenzweig SA. IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun. .342(3):851-8, 2006.
View in: PubMed

14.Kibbey MM, Jameson MJ, Eaton EM, Rosenzweig SA. Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding. Mol Pharmacol. .69(3):833-45, 2005.
View in: PubMed

15.Rosenzweig SA. What's new in the IGF-binding proteins? Growth Horm IGF Res. .14(5):329-36, 2004. PMCID: PMC3347923
View in: PubMed

16.Robinson SA, Rosenzweig SA. Synthesis and characterization of biotinylated forms of insulin-like growth factor-1: topographical evaluation of the IGF-1/IGFBP-2 AND IGFBP-3 interface. Biochemistry. .43(36):11533-45, 2004.
View in: PubMed

17.Slomiany MG, Rosenzweig SA. IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. Invest Ophthalmol Vis Sci. .45(8):2838-47, 2004.
View in: PubMed

18.Slomiany MG, Rosenzweig SA. Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol Cell Physiol. .287(3):C746-53, 2004.
View in: PubMed

19.Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, Neville B, Richardson MS, Rosenzweig S, Sharma AK, Smith MM, Stewart S, Stuart RK. Oral cancer treatment. Curr Treat Options Oncol. .4(1):27-41, 2003.
View in: PubMed

20.Horney MJ, Evangelista CA, Rosenzweig SA. Synthesis and characterization of insulin-like growth factor (IGF)-1 photoprobes selective for the IGF-binding proteins (IGFBPS). photoaffinity labeling of the IGF-binding domain on IGFBP-2. J Biol Chem. .276(4):2880-9, 2000.
View in: PubMed

21.Horney MJ, Shirley DW, Kurtz DT, Rosenzweig SA. Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am J Physiol. .274(6 Pt 2):F1045-53, 1998.
View in: PubMed

22.Lu G, Meier KE, Jaffa AA, Rosenzweig SA, Egan BM. Oleic acid and angiotensin II induce a synergistic mitogenic response in vascular smooth muscle cells. Hypertension. .31(4):978-85, 1998.
View in: PubMed

23.Jaffa AA, Miller BS, Rosenzweig SA, Naidu PS, Velarde V, Mayfield RK. Bradykinin induces tubulin phosphorylation and nuclear translocation of MAP kinase in mesangial cells. Am J Physiol. .273(6 Pt 2):F916-24, 1997.
View in: PubMed

24.Zhang P, Miller BS, Rosenzweig SA, Bhat NR. Activation of C-jun N-terminal kinase/stress-activated protein kinase in primary glial cultures. J Neurosci Res. .46(1):114-21, 1996.
View in: PubMed

25.Lu G, Morinelli TA, Meier KE, Rosenzweig SA, Egan BM. Oleic acid-induced mitogenic signaling in vascular smooth muscle cells. A role for protein kinase C. Circ Res. .79(3):611-8, 1996.
View in: PubMed

26.Miller BS, Shankavaram UT, Horney MJ, Gore AC, Kurtz DT, Rosenzweig SA. Activation of cJun NH2-terminal kinase/stress-activated protein kinase by insulin. Biochemistry. .35(26):8769-75, 1996.
View in: PubMed

27.Law NM, Rosenzweig SA. Neuronal insulin receptors in Y79 retinoblastoma cells. Biochem Biophys Res Commun. .210(1):58-66, 1995.
View in: PubMed

28.Horio B, Law NM, Rosenzweig SA. Characterization of vasoactive intestinal peptide receptors in rabbit ciliary processes. Invest Ophthalmol Vis Sci. .36(1):192-9, 1995.
View in: PubMed

29.Law NM, Rosenzweig SA. Characterization of the G-protein linked orphan receptor GPRN1/RDC1. Biochem Biophys Res Commun. .201(1):458-65, 1994.
View in: PubMed

30.Goetzl EJ, Patel DR, Kishiyama JL, Smoll AC, Turck CW, Law NM, Rosenzweig SA, Sreedharan SP. Specific recognition of the human neuroendocrine receptor for vasoactive intestinal peptide by anti-peptide antibodies. Mol Cell Neurosci. .5(2):145-52, 1994.
View in: PubMed

31.Rosenzweig SA, Oemar BS, Law NM, Shankavaram UT, Miller BS. Insulin like growth factor 1 receptor signal transduction to the nucleus. Adv Exp Med Biol. .343:159-68, 1993.
View in: PubMed

32.Zetterström C, Benjamin A, Rosenzweig SA. Differential expression of retinal insulin receptors in STZ-induced diabetic rats. Diabetes. .41(7):818-25, 1992.
View in: PubMed

33.Oemar BS, Law NM, Rosenzweig SA. Insulin-like growth factor-1 induces tyrosyl phosphorylation of nuclear proteins. J Biol Chem. .266(36):24241-4, 1991.
View in: PubMed

34.Vignery A, Raymond MJ, Qian HY, Wang F, Rosenzweig SA. Multinucleated rat alveolar macrophages express functional receptors for calcitonin. Am J Physiol. .261(6 Pt 2):F1026-32, 1991.
View in: PubMed

35.Dardevet D, Komori K, Grunfeld C, Rosenzweig SA, Buse MG. Increased hepatic insulin proreceptor-to-receptor ratio in diabetes: a possible processing defect. Am J Physiol. .261(5 Pt 1):E562-71, 1991.
View in: PubMed

36.Zetterström C, Fang C, Benjamin A, Rosenzweig SA. Characterization of a novel receptor in toad retina with dual specificity for insulin and insulin-like growth factor I. J Neurochem. .57(4):1332-9, 1991.
View in: PubMed

37.Raymond MJ, Rosenzweig SA. Vasoactive intestinal peptide receptors on AR42J rat pancreatic acinar cells. Biochem Biophys Res Commun. .179(1):176-82, 1991.
View in: PubMed

38.Oemar BS, Foellmer HG, Hodgdon-Anandant L, Rosenzweig SA. Regulation of insulin-like growth factor I receptors in diabetic mesangial cells. J Biol Chem. .266(4):2369-73, 1991.
View in: PubMed

39.Rosenzweig SA, Zetterström C, Benjamin A. Identification of retinal insulin receptors using site-specific antibodies to a carboxyl-terminal peptide of the human insulin receptor alpha-subunit. Up-regulation of neuronal insulin receptors in diabetes. J Biol Chem. .265(29):18030-4, 1990.
View in: PubMed

40.Swedlund AP, Rosenzweig SA. Characterization of vasoactive intestinal peptide receptors in retina. Exp Eye Res. .51(3):317-23, 1990.
View in: PubMed

41.Bone EA, Rosenzweig SA. Characterization of cholecystokinin receptors in toad retina. Peptides. .9(2):373-81, 1988.
View in: PubMed

42.Madison LD, Jamieson JD, Rosenzweig SA. Heterogeneity of cholecystokinin receptors in pancreas. Biochem Biophys Res Commun. .143(2):761-7, 1987.
View in: PubMed

43.Madison LD, Rosenzweig SA, Jamieson JD. Use of the heterobifunctional cross-linker m-maleimidobenzoyl N-hydroxysuccinimide ester to affinity label cholecystokinin binding proteins on rat pancreatic plasma membranes. J Biol Chem. .259(23):14818-23, 1984.
View in: PubMed

44.Rosenzweig SA, Madison LD, Jamieson JD. Analysis of cholecystokinin-binding proteins using endo-beta-N-acetylglucosaminidase F. J Cell Biol. .99(3):1110-6, 1984. PMCID: PMC2113376
View in: PubMed